Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.It has been roughly six months since my last Nuvalent (NASDAQ: NUVL ) article , where I discussed NVL-655’s blockbuster potential following the FDA’s decision to grant the company’s ALK-selective inhibitor, NVL-655 their Breakthrough Therapy Designation ...